- Home
- NBP vs ZVRA Comparison
NBP vs ZVRA Comparison
Compare NBP & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | ZVRA |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBP | ZVRA |
|---|---|---|
| Price | $3.11 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $21.71 |
| AVG Volume (30 Days) | 432.4K | ★ 547.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $6.19 |
| 52 Week High | $5.19 | $13.16 |
Technical Indicators
Market Signals| Indicator | NBP | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 53.39 |
| Support Level | $3.04 | $8.61 |
| Resistance Level | $3.74 | $8.99 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 17.78 | 71.05 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.